Glucon says trial results are positive for Aprise glucose-monitoring device

By E. Janene Geiss

Philadelphia, Nov. 10 - Glucon announced Thursday that a recent trial of its flagship product Aprise, a continuous, non-invasive glucose monitoring device, demonstrated positive results.

Three different protocols with 30 subjects were employed to test Aprise, according to a company news release.

In the first protocol, rapid glucose variations were induced by venous infusion of dextrose solution and insulin. In the second protocol, the glucose level was increased by drinking a glucose solution and decreased by the diabetic subject's regular medications. And in the third protocol the glucose level was raised with a regular meal and decreased again by the diabetic subject's regular medications, officials said.

The prospective results were a mean absolute relative deviation of 19%, Dr. Benny Pesach, Glucon's vice president of research and development, said in the release.

"There are several companies in the glucose monitoring space racing to develop an accurate, non-invasive system. Data collected with Glucon's Aprise showed that the technology has surpassed that of the competition in terms of accuracy and speed. Glucon's Aprise provides a glucose measurement every three seconds. It is also light weight, compact, comfortable, impressively accurate and the most clinically advanced," Ron Nager, Glucon's president, said in the release.

The data was presented Thursday at the Diabetes Technology Society Standards Workshop at the Fifth Annual Diabetes Technology Meeting. Glucon also will be presenting data at Medica, the upcoming 37th World Forum for Medicine at the Dusseldorf Trade Fair Centre in Dusseldorf, Germany.

In other news, the company said it has secured an option to license several photoacoustic technology patents, granted to a group of scientists at the University of Texas Medical Branch in Galveston, Tex.

Boulder, Colo.-based Glucon is developing Aprise for home and clinical use. The device is currently undergoing extensive clinical trials.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.